ResearcherTezcat Biosciences, Inc.Active in the last 2 years

Craig Patrick Ramirez

Verified by NIH RePORTER profile ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on NIH RePORTER profile ID 11572150. Sources: NIH RePORTER.

Their work

Papers: 0
Trials: 0
Grants: 3
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 1 grant · 2023: none · 2024: none · 2025: none · 2026: 2 grants

Grants 3

Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer. R41CA306696 ↗
A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer. R44CA265512 ↗
A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer. R41CA265512 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ali Azhdarinia · 1 shared grant, 2026 · strength 1.26
- Grant Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer. R41CA306696 ↗
Shohei Koide · 1 shared grant, 2022 · strength 0.52
- Grant A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer. R41CA265512 ↗
Dafna Bar‐Sagi · 1 shared grant, 2022 · strength 0.52
- Grant A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer. R41CA265512 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.